| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4532-4541. Prepublished online as a Blood First Edition Paper on August 20, 2008; DOI 10.1182/blood-2008-01-131417.
Submitted January 2, 2008
Gene Therapy Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States * Corresponding author; email: paul_monahan{at}med.unc.edu.
Hemophilic bleeding into joints causes synovial and microvascular proliferation and inflammation (hemophilic synovitis) that contribute to end-stage joint degeneration (hemophilic arthropathy), the major morbidity of hemophilia. New therapies are needed for joint deterioration that progresses despite standard intravenous (IV) clotting factor replacement. To test whether factor IX within the joint space can protect joints from hemophilic synovitis, we established a hemophilia B mouse model of synovitis. Factor IX knockout (FIX-/-) mice received a puncture of the knee joint capsule with a needle to induce hemarthrosis; human factor IX (hFIX) was either injected through the needle into the joint space (intraarticularly, IA) or immediately delivered IV. FIX-/- mice receiving IA FIX protein were protected from synovitis compared with mice receiving same or greater doses of hFIX IV. Next, adeno-associated virus (AAV) gene transfer vectors expressing hFIX were injected into knee joints of FIX-/- mice. Joints treated with 1 x 1010 vector genomes (vg)/joint AAV2-, AAV5-, or AAV8-hFIX or 2.5 x 109 vg/joint AAV5-hFIX developed significantly fewer pathologic changes two weeks post-injury as compared to the pathology of control injured contralateral hindlimbs. Extravascular factor activity and joint-directed gene transfer may ameliorate hemophilic joint destruction, even in the absence of circulating FIX.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||